Karuna Therapeutics is a Massachusetts-based developer of drugs for the treatment of schizophrenia.
Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 9, 2022 | Post-IPO Equity | $750M | — | — | — | Detail |
Mar 1, 2021 | Post-IPO Equity | $250M | — | — | — | Detail |
Jun 27, 2019 | IPO | $89.24M | — | — | — | Detail |
Mar 18, 2019 | Series B | $68M | 10 |
![]() |
— | Detail |
Aug 2, 2018 | Series A | $42M | 4 |
![]() |
— | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
![]() |
Yes | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |
![]() |
— | Series B |